Trial Profile
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL™ II China
- Sponsors Novo Nordisk
- 01 Dec 2021 Results published in the Diabetes, Obesity and Metabolism
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 12 Mar 2020 Primary endpoint (Change in HbA1c) has been met as per results published in the ClinicalTrials.gov Trial Registry